WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
5,20 ฿
0,00%
(0,00) 1 d.
15. okt., 16:40:00 GMT+7 · THB
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: WUXI06…
Atvērt
5,25 ฿
Augsta
5,35 ฿
Zema
5,05 ฿
Tirgus kapitalizācija
198,02 mljrd.
Vid. apjoms
93,60 tūkst.
Apjoms
288,50 tūkst.
Augstākā 52 ned.
6,25 ฿
Zemākā 52 ned.
3,02 ฿
Apgrozībā esošās akcijas
4,12 mljrd.
Darbinieku skaits
15 tūkst.
Atvērt
5,25 ฿
Augsta
5,35 ฿
Zema
5,05 ฿
Tirgus kapitalizācija
198,02 mljrd.
Vid. apjoms
93,60 tūkst.
Apjoms
288,50 tūkst.
Augstākā 52 ned.
6,25 ฿
Zemākā 52 ned.
3,02 ฿
Apgrozībā esošās akcijas
4,12 mljrd.
Darbinieku skaits
15 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
TradingView
·
pirms 50 minūtēm
Key facts: NASDAQ:ASTS delayed 2027; Piper Sandler Neutral; $1B note
Moomoo
·
pirms 46 minūtēm
Dow Jones Top Company Headlines at 3 AM ET: Tesla's New Roadster Takes Flight After Nearly a Decade of Delays | Schneider ...
Kalkine Media
·
pirms 10 minūtēm
Could Meta Platforms (NASDAQ:META) Be in Focus After Wall Street’s Latest Rotation?
Investor's Business Daily
·
pirms 4 stundām
Futures Mixed; Anthropic Value, Tesla Roadster In Focus
Profils
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Par “Wuxi Biologics (Cayman) Inc. KKPS DR”
ĢenerāldirektorsZhisheng Chen
Darbinieki14,7 tūkst.
Dibināšanas datums2010
Galvenais birojs-
Sektors-
Tīmekļa vietnewuxibiologics.com